'Dramatic' early phase 1 results for AG-120 in IDH1 mutated AML
Tuesday, November 25, 2014 - 15:32
in Health & Medicine
A new study shows "extremely promising” early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in the gene IDH.